Agency Information Collection Activities; Proposed Collection; Comment Request; Generic Clearance for the Collection of Qualitative Feedback on Agency Service Delivery, 23980-23981 [2014-09693]
Download as PDF
<![CDATA[
23980
Federal Register / Vol. 79, No. 82 / Tuesday, April 29, 2014 / Notices
(3) train state and local personnel in
health work. The BSC, NCEH/ATSDR
provides advice and guidance to the
Secretary, HHS; the Director, CDC and
Administrator, ATSDR; and the
Director, NCEH/ATSDR, regarding
program goals, objectives, strategies, and
priorities in fulfillment of the agency’s
mission to protect and promote people’s
health. The board provides advice and
guidance that will assist NCEH/ATSDR
in ensuring scientific quality,
timeliness, utility, and dissemination of
results. The board also provides
guidance to help NCEH/ATSDR work
more efficiently and effectively with its
various constituents and to fulfill its
mission in protecting America’s health.
Matters for Discussion: The agenda
items for the BSC Meeting will include
NCEH/ATSDR Office of the Director
updates; CDC Winnable Battles: Food
Safety; consideration of a subcommittee
to the BSC for childhood lead poisoning
prevention; vote on recommendation
regarding a subcommittee to the BSC for
childhood lead poisoning prevention;
radiation preparedness planning;
NCEH/ATSDR Strategic Planning and
Priorities; NCEH/ATSDR Priority: Water
Safety; updates from the National
Institute for Environmental Health
Services, National Institute for
Occupational Safety and Health, U.S.
Department of Energy and the U.S.
Environmental Protection Agency;
NCEH/ATSDR Response to Prior BSC
Guidance; discussion of future BSC
agenda topics and action items.
Agenda items are subject to change as
priorities dictate.
The
public comment period is scheduled on
Thursday, May 22, 2014 from 3:00 p.m.
until 3:15 p.m., and on Friday, May 23,
2014 from 10:45 a.m. until 11:00 a.m.
Contact Person for More Information:
Sandra Malcom, Committee
Management Specialist, NCEH/ATSDR,
4770 Buford Highway, Mail Stop F–61,
Chamblee, Georgia 30345; Telephone
770/488–0575 or 770/488–0755, Fax:
770/488–3377; Email: smalcom@
cdc.gov. The deadline for notification of
attendance is May 16, 2014.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities for both the
Centers for Disease Control and
sroberts on DSK5SPTVN1PROD with NOTICES
SUPPLEMENTARY INFORMATION:
VerDate Mar<15>2010
16:56 Apr 28, 2014
Jkt 232001
Prevention and the Agency for Toxic
Substances and Disease Registry.
Gary J. Johnson,
Acting Director, Management Analysis and
Services Office Centers for Disease Control
and Prevention.
[FR Doc. 2014–09702 Filed 4–28–14; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2014–N–0487]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Generic Clearance
for the Collection of Qualitative
Feedback on Agency Service Delivery
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing an
opportunity for public comment on the
proposed collection of certain
information by the Agency. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal Agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension of an existing collection of
information, and to allow 60 days for
public comment in response to the
notice. This notice solicits comments on
the collection of information involving
a generic clearance for qualitative
feedback on Agency service delivery.
DATES: Submit either electronic or
written comments on the collection of
information by June 30, 2014.
ADDRESSES: Submit electronic
comments on the collection of
information to https://
www.regulations.gov. Submit written
comments on the collection of
information to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. All
comments should be identified with the
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT: FDA
PRA Staff, Office of Operations, Food
and Drug Administration, 1350 Piccard
Dr., PI50–400B, Rockville, MD 20850,
PRAStaff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3520), Federal
Agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
SUMMARY:
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
Agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information,
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
Generic Clearance for the Collection of
Qualitative Feedback on Agency
Service Delivery (OMB Control Number
0697)—Extension
The information collection activity
will garner qualitative customer and
stakeholder feedback in an efficient,
timely manner, in accordance with the
Administration’s commitment to
improving service delivery. By
qualitative feedback we mean
information that provides useful
insights on perceptions and opinions,
but are not statistical surveys that yield
quantitative results that can be
generalized to the population of study.
This feedback will provide insights into
customer or stakeholder perceptions;
experiences and expectations; provide
an early warning of issues with service;
or focus attention on areas where
communication, training, or changes in
operations might improve delivery of
products or services. These collections
will allow for ongoing collaborative and
actionable communications between the
Agency and its customers and
stakeholders. It will also allow feedback
E:\FR\FM\29APN1.SGM
29APN1
Federal Register / Vol. 79, No. 82 / Tuesday, April 29, 2014 / Notices
to contribute directly to the
improvement of program management.
Feedback collected under this generic
clearance will provide useful
information, but it will not yield data
that can be generalized to the overall
population. This type of generic
clearance for qualitative information
will not be used for quantitative
information collections that are
designed to yield reliably actionable
results, such as monitoring trends over
time or documenting program
performance. Such data uses require
more rigorous designs that address the
following: The target population to
which generalizations will be made, the
sampling frame, the sample design
(including stratification and clustering),
the precision requirements or power
calculations that justify the proposed
sample size, the expected response rate,
methods for assessing potential nonresponse bias, the protocols for data
23981
collection, and any testing procedures
that were or will be undertaken prior to
fielding the study. Depending on the
degree of influence the results are likely
to have, such collections may still be
eligible for submission for other generic
mechanisms that are designed to yield
quantitative results.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Number of
respondents
Activity
Focus groups .......................................................
Customer comment cards/forms ..........................
Small discussion groups ......................................
Customer satisfaction surveys .............................
725
1,200
725
6,450
Total ..............................................................
Number of
responses per
respondent
1
1
1
1
725
1,200
725
6,450
[FR Doc. 2014–09693 Filed 4–28–14; 8:45 am]
OMB control number 0910–0027. Also
include the FDA docket number found
in brackets in the heading of this
document.
BILLING CODE 4160–01–P
FOR FURTHER INFORMATION CONTACT:
FDA
PRA Staff, Office of Operations, Food
and Drug Administration, 1350 Piccard
Dr., PI50–400B, Rockville, MD 20850,
PRAStaff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–N–0623]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Voluntary
Cosmetic Registration Program
Food and Drug Administration,
HHS.
ACTION:
1,269
300
1,269
2,129
are no capital costs or operating and maintenance costs associated with this collection of information.
Dated: April 23, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
AGENCY:
1 hour, 45 minutes ........
15 minutes ....................
1 hour, 45 minutes ........
20 minutes ....................
Total hours
4,967
1 There
Notice.
The Food and Drug
Administration (FDA or we) is
announcing that a proposed collection
of information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by May 29,
2014.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–7285, or emailed to oira_
submission@omb.eop.gov. All
comments should be identified with the
SUMMARY:
sroberts on DSK5SPTVN1PROD with NOTICES
Average
burden per
response
Total annual
responses
VerDate Mar<15>2010
19:08 Apr 28, 2014
Jkt 232001
Voluntary Cosmetic Registration
Program—21 CFR Parts 710 and 720
(OMB Control Number 0910–0027)—
Extension
The Federal Food, Drug, and Cosmetic
Act (the FD&C Act) provides us with the
authority to regulate cosmetic products
in the United States. Cosmetic products
that are adulterated under section 601 of
the FD&C Act (21 U.S.C. 361) or
misbranded under section 602 of the
FD&C Act (21 U.S.C. 362) may not be
distributed in interstate commerce. We
have developed the VCRP to assist us in
carrying out our responsibility to
regulate cosmetics.
In 21 CFR part 710, we request that
establishments that manufacture or
package cosmetic products register with
us on Form FDA 2511 entitled
‘‘Registration of Cosmetic Product
Establishment.’’ The term ‘‘Form FDA
2511’’ refers to both the paper and
electronic versions of the form. The
electronic version of Form FDA 2511 is
available on our VCRP Web site at
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
https://www.fda.gov/Cosmetics/
RegistrationProgram/
OnlineRegistration/ucm090947.htm. We
strongly encourage electronic
registration of Form FDA 2511 because
it is faster and more convenient. A
registering facility will receive
confirmation of electronic registration,
including a registration number, by
email, usually within 7 business days.
The online system also allows for
amendments to past submissions.
Because registration of cosmetic
product establishments is not
mandatory, voluntary registration
provides us with the best information
available about the locations, business
trade names, and types of activity
(manufacturing or packaging) of
cosmetic product establishments. We
place the registration information in a
computer database and use the
information to generate mailing lists for
distributing regulatory information and
for inviting firms to participate in
workshops on topics in which they may
be interested. We also use the
information for estimating the size of
the cosmetic industry and for
conducting onsite establishment
inspections. Registration is permanent,
although we request that respondents
submit an amended Form FDA 2511 if
any of the originally submitted
information changes.
In part 720 (21 CFR part 720), we
request that firms that manufacture,
pack, or distribute cosmetics file with us
an ingredient statement for each of their
products. Ingredient statements for new
submissions (§§ 720.1 through 720.4)
are reported on Form FDA 2512,
E:\FR\FM\29APN1.SGM
29APN1
]]>Agencies
[Federal Register Volume 79, Number 82 (Tuesday, April 29, 2014)]
[Notices]
[Pages 23980-23981]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-09693]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2014-N-0487]
Agency Information Collection Activities; Proposed Collection;
Comment Request; Generic Clearance for the Collection of Qualitative
Feedback on Agency Service Delivery
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing an
opportunity for public comment on the proposed collection of certain
information by the Agency. Under the Paperwork Reduction Act of 1995
(the PRA), Federal Agencies are required to publish notice in the
Federal Register concerning each proposed collection of information,
including each proposed extension of an existing collection of
information, and to allow 60 days for public comment in response to the
notice. This notice solicits comments on the collection of information
involving a generic clearance for qualitative feedback on Agency
service delivery.
DATES: Submit either electronic or written comments on the collection
of information by June 30, 2014.
ADDRESSES: Submit electronic comments on the collection of information
to https://www.regulations.gov. Submit written comments on the
collection of information to the Division of Dockets Management (HFA-
305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852. All comments should be identified with the docket
number found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations,
Food and Drug Administration, 1350 Piccard Dr., PI50-400B, Rockville,
MD 20850, PRAStaff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
Agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal Agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information, including
each proposed extension of an existing collection of information,
before submitting the collection to OMB for approval. To comply with
this requirement, FDA is publishing notice of the proposed collection
of information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
Generic Clearance for the Collection of Qualitative Feedback on Agency
Service Delivery (OMB Control Number 0697)--Extension
The information collection activity will garner qualitative
customer and stakeholder feedback in an efficient, timely manner, in
accordance with the Administration's commitment to improving service
delivery. By qualitative feedback we mean information that provides
useful insights on perceptions and opinions, but are not statistical
surveys that yield quantitative results that can be generalized to the
population of study. This feedback will provide insights into customer
or stakeholder perceptions; experiences and expectations; provide an
early warning of issues with service; or focus attention on areas where
communication, training, or changes in operations might improve
delivery of products or services. These collections will allow for
ongoing collaborative and actionable communications between the Agency
and its customers and stakeholders. It will also allow feedback
[[Page 23981]]
to contribute directly to the improvement of program management.
Feedback collected under this generic clearance will provide useful
information, but it will not yield data that can be generalized to the
overall population. This type of generic clearance for qualitative
information will not be used for quantitative information collections
that are designed to yield reliably actionable results, such as
monitoring trends over time or documenting program performance. Such
data uses require more rigorous designs that address the following: The
target population to which generalizations will be made, the sampling
frame, the sample design (including stratification and clustering), the
precision requirements or power calculations that justify the proposed
sample size, the expected response rate, methods for assessing
potential non-response bias, the protocols for data collection, and any
testing procedures that were or will be undertaken prior to fielding
the study. Depending on the degree of influence the results are likely
to have, such collections may still be eligible for submission for
other generic mechanisms that are designed to yield quantitative
results.
FDA estimates the burden of this collection of information as
follows:
Table 1--Estimated Annual Reporting Burden \1\
----------------------------------------------------------------------------------------------------------------
Number of
Activity Number of responses per Total annual Average burden Total hours
respondents respondent responses per response
----------------------------------------------------------------------------------------------------------------
Focus groups.................. 725 1 725 1 hour, 45 1,269
minutes.
Customer comment cards/forms.. 1,200 1 1,200 15 minutes...... 300
Small discussion groups....... 725 1 725 1 hour, 45 1,269
minutes.
Customer satisfaction surveys. 6,450 1 6,450 20 minutes...... 2,129
---------------------------------------------------------------------------------
Total..................... 4,967
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
Dated: April 23, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014-09693 Filed 4-28-14; 8:45 am]
BILLING CODE 4160-01-P
